The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
The accelerated review covers WCK 5222 for multiple critical infections
Captured microbes are then neutralized on engineered microbicidal surfaces
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Subscribe To Our Newsletter & Stay Updated
